| Literature DB >> 31168412 |
Anna Karin Hedström1,2, Ola Hössjer3, Lars Klareskog4, Lars Alfredsson2.
Abstract
Objectives: The relationship between alcohol consumption and risk for rheumatoid arthritis (RA) is incompletely understood. We aimed to determine the influence of alcohol on anticitrullinated protein antibody (ACPA) positive and ACPA-negative RA and investigate potential interactions between alcohol consumption, smoking and the presence of human leucocyte antigen (HLA)-DRB1-shared epitope (SE).Entities:
Keywords: ant-ccp; epidemiology; gene polymorphism; rheumatoid arthritis; smoking
Year: 2019 PMID: 31168412 PMCID: PMC6525609 DOI: 10.1136/rmdopen-2019-000893
Source DB: PubMed Journal: RMD Open ISSN: 2056-5933
OR with 95% CI of developing RA for different categories of alcohol consumers compared with never drinkers, in total and stratified by gender
| Alcohol consumption | Total | ACPA-positive RA | ACPA-negative RA | |||
| CA/CO* | OR (95% CI)† | CA/CO* | OR (95% CI)† | CA/CO* | OR (95% CI)† | |
| Never | 930/431 | 1.0 (reference) | 621/431 | 1.0 (reference) | 309/431 | 1.0 (reference) |
| Low | 1324/1180 | 0.57 (0.49 to 0.66) | 883/1180 | 0.54 (0.46 to 0.64) | 441/1180 | 0.62 (0.51 to 0.76) |
| Moderate | 624/627 | 0.49 (0.41 to 0.58) | 393/627 | 0.43 (0.36 to 0.52) | 231/627 | 0.59 (0.47 to 0.74) |
| High | 475/598 | 0.38 (0.31 to 0.45) | 296/598 | 0.33 (0.27 to 0.41) | 179/598 | 0.47 (0.37 to 0.60) |
| <0.0001‡ | <0.0001‡ | 0.005‡ | ||||
| Women | ||||||
| Never | 733/353 | 1.0 (reference) | 492/353 | 1.0 (reference) | 241/353 | 1.0 (reference) |
| Low | 1038/963 | 0.57 (0.48 to 0.68) | 699/963 | 0.54 (0.45 to 0.65) | 339/963 | 0.63 (0.51 to 0.79) |
| Moderate | 421/461 | 0.47 (0.39 to 0.57) | 265/461 | 0.41 (0.33 to 0.51) | 156/461 | 0.60 (0.46 to 0.78) |
| High | 212/295 | 0.37 (0.29 to 0.47) | 131/295 | 0.31 (0.24 to 0.41) | 81/295 | 0.49 (0.36 to 0.68) |
| <0.0001‡ | <0.0001‡ | 0.003‡ | ||||
| Men | ||||||
| Never | 197/78 | 1.0 (reference) | 129/78 | 1.0 (reference) | 68/78 | 1.0 (reference) |
| Low | 286/217 | 0.57 (0.41 to 0.80) | 184/217 | 0.55 (0.38 to 0.79) | 102/217 | 0.60 (0.39 to 0.91) |
| Moderate | 203/166 | 0.53 (0.38 to 0.76) | 128/166 | 0.51 (0.35 to 0.75) | 75/116 | 0.58 (0.37 to 0.90) |
| High | 263/303 | 0.39 (0.28 to 0.54) | 165/303 | 0.36 (0.25 to 0.52) | 98/303 | 0.43 (0.28 to 0.66) |
| <0.0001‡ | <0.0001‡ | 0.2‡ | ||||
Low alcohol consumption means less than approximately four glasses of alcohol per week; moderate alcohol consumption means approximately four to seven glasses of alcohol per week; high alcohol consumption means approximatley eight or more glasses of alcohol per week.
*Number of exposed CA and CO.
†Adjusted for age, gender, residential area, ancestry, smoking, human leucocyte antigen-DRB1 shared epitope and study.
‡P value for trend,
ACPA, anticitrullinated protein antibodies; CA, cases; CO, controls; RA, rheumatoid arthritis.
Figure 1Dose–response relationship between the weekly amount of alcohol consumption and risk of developing RA. ACPA, anticitrullinated protein antibodies; RA, rheumatoid arthritis.
OR with 95% CI of developing RA for subjects with different combinations of HLA-SE and alcohol consumption, compared with HLA-SE negative subjects who consume alcohol, in total and stratified by smoking status
| HLA-SE | Non-drinking | RA | ACPA-positive RA | ACPA-negative RA | |||
| CA/CO* | OR (95% CI)† | CA/CO* | OR (95% CI)† | CA/CO* | OR (95% CI)† | ||
| − | − | 652/1139 | 1.0 (reference) | 259/1139 | 1.0 (reference) | 393/1139 | 1.0 (reference) |
| − | + | 241/220 | 1.7 (1.4 to 2.1) | 91/220 | 1.7 (1.3 to 2.3) | 150/220 | 1.7 (1.3 to 2.2) |
| + | − | 1771/1266 | 2.4 (2.2 to 2.8) | 1313/1266 | 4.6 (3.9 to 5.4) | 458/1266 | 1.0 (0.9 to 1.2) |
| + | + | 689/211 | 5.3 (4.3 to 6.5) | 530/211 | 11.0 (8.8 to 13.7) | 159/211 | 1.8 (1.4 to 2.4) |
| AP 0.4 (0.2 to 0.5)§ | AP 0.5 (0.4 to 0.6)§ | AP −0.03 (−0.4 to 0.3)§ | |||||
| − | − | 214/476 | 1.0 (reference) | 72/476 | 1.0 (reference) | 142/476 | 1.0 (reference) |
| − | + | 120/116 | 2.0 (1.4 to 2.7) | 44/116 | 2.2 (1.4 to 3.5) | 76/116 | 1.8 (1.2 to 2.6) |
| + | − | 528/524 | 2.2 (1.8 to 2.8) | 367/524 | 4.8 (3.6 to 6.6) | 161/524 | 1.0 (0.8 to 1.4) |
| + | + | 251/108 | 4.7 (3.4 to 6.3) | 171/108 | 10.5 (7.2 to 15.4) | 80/108 | 2.0 (1.3 to 2.8) |
| AP 0.2 (−0.02 to 0.5)§ | AP 0.4 (0.2 to 0.6)§ | AP −0.04 (−0.5 to 0.4)§ | |||||
| − | − | 438/663 | 1.0 (reference) | 187/663 | 1.0 (reference) | 251/663 | 1.0 (reference) |
| − | + | 121/104 | 1.6 (1.2 to 2.2) | 47/104 | 1.6 (1.1 to 2.4) | 74/104 | 1.7 (1.2 to 2.3) |
| + | − | 1243/742 | 2.5 (2.2 to 2.9) | 946/742 | 4.5 (3.7 to 5.5) | 297/742 | 1.0 (0.9 to 1.3) |
| + | + | 438/103 | 6.3 (4.8 to 8.1) | 359/103 | 12.8 (9.6 to 17.1) | 79/103 | 1.8 (1.3 to 2.5) |
| AP 0.5 (0.3 to 0.6)§ | AP 0.6 (0.5 to 0.7)§ | AP −0.02 (−0.5 to 0.4)§ | |||||
*Number of exposed CA and CO.
†Adjusted for age, gender, residential area, ancestry, smoking and study.
‡Adjusted for age, gender, residential area, ancestry and study.
§AP due to interaction with 95% CI.
ACPA, anticitrullinated protein antibodies; AP, attributable proportion; CA, cases; CO, controls; HLA-SE, human leucocyte antigen-shared epitope; RA, rheumatoid arthritis.
OR with 95% CI of developing RA for subjects with different combinations of alcohol and smoking habits, compared with never smokers who consume alcohol, in total and stratified by HLA-SE status
| Non-drinking | Smoking | RA | ACPA-positive RA | ACPA-negative RA | |||
| CA/CO* | OR (95% CI)† | CA/CO* | OR (95% CI)† | CA/CO* | OR (95% CI)† | ||
| − | − | 742/1000 | 1.0 (reference) | 439/1000 | 1.0 (reference) | 303/1000 | 1.0 (reference) |
| − | + | 1681/1405 | 1.7 (1.5 to 1.9) | 1133/1405 | 2.0 (1.7 to 2.3) | 548/1405 | 1.2 (1.0 to 1.4) |
| + | − | 371/224 | 2.1 (1.7 to 2.6) | 215/224 | 2.2 (1.7 to 2.8) | 156/224 | 2.0 (1.5 to 2.5) |
| + | + | 559/207 | 3.5 (2.9 to 4.3) | 406/207 | 4.8 (3.8 to 5.9) | 153/207 | 2.0 (1.5 to 2.6) |
| 0.2 (0.03 to 0.4) | 0.3 (0.2 to 0.5) | −0.08 (−0.4 to 0.3) | |||||
| − | − | 214/476 | 1.0 (reference) | 72/476 | 1.0 (reference) | 142/476 | 1.0 (reference) |
| − | + | 438/663 | 1.5 (1.2 to 1.9) | 187/663 | 2.1 (1.5 to 2.8) | 251/663 | 1.4 (1.0 to 1.8) |
| + | − | 120/116 | 2.2 (1.6 to 3.0) | 44/116 | 2.6 (1.6 to 4.1) | 76/116 | 2.3 (1.6 to 3.3) |
| + | + | 121/104 | 2.4 (1.8 to 3.4) | 47/104 | 3.2 (2.1 to 5.1) | 74/104 | 2.4 (1.6 to 3.5) |
| −0.04 (−0.4 to 0.4) | −0.09 (-0.5 to 0.4) | −0.1 (−0.6 to 0.4) | |||||
| − | − | 528/524 | 1.0 (reference) | 367/524 | 1.0 (reference) | 161/524 | 1.0 (reference) |
| − | + | 1243/742 | 1.7 (1.5 to 2.0) | 946/742 | 2.0 (1.7 to 2.4) | 297/742 | 1.2 (1.0 to 1.5) |
| + | − | 251/108 | 2.2 (1.7 to 2.9) | 171/108 | 2.3 (1.7 to 3.1) | 80/108 | 1.9 (1.3 to 2.8) |
| + | + | 438/103 | 4.1 (3.2 to 5.4) | 359/103 | 5.3 (4.0 to 7.1) | 79/103 | 1.9 (1.3 to 2.8) |
| 0.3 (0.1 to 0.5) | 0.4 (0.2 to 0.6) | −0.1 (−0.6 to 0.4) | |||||
*Number of exposed CA and CO.
†Adjusted for age, gender, residential area, ancestry, HLA-SE status and study.
‡Adjusted for age, gender, residential area, ancestry and study.
ACPA, anticitrullinated protein antibodies; CA, cases; CO, controls; HLA-SE, human leucocyte antigen-shared epitope; RA, rheumatoid arthritis.
OR with 95% CI of developing RA for subjects with different combinations of alcohol consumption, smoking habits and HLA-SE status, compared with HLA-SE negative never smokers who consume alcohol
| Non-drinking | Smoking | HLA-SE | Total | ACPA-positive RA | ACPA-negative RA | |||
| CA/CO* | OR (95% CI)† | CA/CO* | OR (95% CI)† | CA/CO* | OR (95% CI)† | |||
| − | − | − | 214/476 | 1.0 (reference) | 72/476 | 1.0 (reference) | 142/476 | 1.0 (reference) |
| − | + | − | 438/663 | 1.5 (1.2 to 1.9) | 187/663 | 2.0 (1.5 to 2.8) | 251/663 | 1.2 (1.0 to 1.6) |
| + | − | − | 120/116 | 2.1 (1.5 to 2.9) | 44/116 | 2.4 (1.5 to 3.8) | 76/116 | 1.9 (1.3 to 2.7) |
| + | + | − | 121/104 | 2.4 (1.7 to 3.3) | 47/104 | 3.1 (2.0 to 4.8) | 74/104 | 2.0 (1.4 to 2.8) |
| − | − | + | 528/524 | 2.2 (1.8 to 2.7) | 367/524 | 4.7 (3.5 to 6.3) | 161/524 | 1.0 (0.8 to 1.5) |
| − | + | + | 1243/742 | 3.9 (3.2 to 4.7) | 946/742 | 9.3 (7.0 to 12.3) | 297/742 | 1.3 (1.0 to 1.6) |
| + | − | + | 251/108 | 5.0 (3.7 to 6.7) | 171/108 | 11.0 (7.6 to 15.9) | 80/108 | 2.1 (1.4 to 3.0) |
| + | + | + | 438/103 | 9.2 (6.9 to 12.2) | 359/103 | 25.3 (17.7 to 36.2) | 79/103 | 2.1 (1.5 to 3.1) |
| AP 0.6 (0.4 to 0.7)‡ | AP 0.7 (0.6 to 0.8)‡ | AP 0.008 (−0.4 to 0.4)‡ | ||||||
*Number of exposed CA and CO.
†Adjusted for age, gender, residential area, ancestry and study.
‡AP due to interaction (95% CI) of the OR due to second-order and third-order interaction between the three risk factors.
§AP due to interaction (95% CI) of the OR due to third-order interaction between the three risk factors.
¶EOR (95% CI) of triple exposed due to third-order interaction between the three risk factors.
ACPA, anticitrullinated protein antibodies; AP, attributable proportion; CA, cases; CO, controls; EOR, excess OR; HLA-SE, human leucocyte antigen-shared epitope; RA, rheumatoid arthritis.
Figure 2Interaction between HLA-DRB1 shared epitope and non-drinking with regard to risk of developing ACPA-positive and ACPA-negative RA, among never smokers and ever smokers. Based on data from table 4. ACPA, anticitrullinated protein antibodies; HLA, human leucocyte antigen; RA, rheumatoid arthritis.